This is a StreetInsider.com Premium Only Page

Can-Fite BioPharma (CANF) – StreetInsider.com Reports

Apr 15, 2024 07:02 AM Can-Fite Bio (CANF) Announces Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 3, 2024 07:02 AM Can-Fite BioPharma (CANF) Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Mar 28, 2024 07:04 AM Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update

Feb 28, 2024 07:01 AM Can-Fite BioPharma (CANF) Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Jan 29, 2024 07:01 AM Can-Fite BioPharma (CANF) Reports Publication Showing Positive Data from COMFORT-1 Phase III Psoriasis Study

Dec 20, 2023 07:04 AM Can-Fite BioPharma (CANF) Reports New Data on Namodenoson’s Anti-obesity Mechanism of Action

Dec 18, 2023 07:00 AM Can-Fite BioPharma (CANF) Received FDA Positive Response to Psoriasis Pediatric Plan

Nov 21, 2023 01:55 PM Can-Fite BioPharma (CANF) Announces Exercise of Warrants for Approximately $3M in Gross Proceeds

Nov 1, 2023 07:03 AM Can-Fite BioPharma (CANF) Issues Business Update

Oct 30, 2023 07:03 AM Can-Fite BioPharma (CANF) Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

Aug 18, 2023 07:00 AM Can-Fite BioPharma (CANF) Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

Jun 29, 2023 07:01 AM Can-Fite BioPharma (CANF) Granted FDA Nod for Piclidenoson Psoriasis Registration Plan

Jun 1, 2023 07:03 AM Can-Fite BioPharma (CANF) Tops Q1 EPS by 19c

Apr 10, 2023 07:00 AM Can-Fite BioPharma (CANF) Announces EMA Green Light for Piclidenoson Pivotal Phase III Trial

Mar 30, 2023 07:15 AM Can-Fite BioPharma (CANF) Reports FY22, Provides Clinical Update

Jan 11, 2023 09:05 AM Can-Fite BioPharma (CANF) Announces $7.5M Share Offering at $5.50/sh

Jan 10, 2023 07:02 AM Can-Fite BioPharma (CANF) Submits Market Registration Plan to EMA for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow

Jan 2, 2023 05:49 AM Can-Fite BioPharma (CANF) Announces ADS Ratio Change to 1:300

Dec 28, 2022 09:34 AM Can-Fite BioPharma (CANF) PT Raised to $8 at Dawson James

Dec 28, 2022 07:01 AM Can-Fite BioPharma (CANF) Announces Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer

Nov 25, 2022 07:02 AM Can-Fite BioPharma (CANF) Tops Q3 EPS by 8c

Nov 2, 2022 07:15 AM Can-Fite BioPharma (CANF) Reports Positive New Data from Phase III Psoriasis Study

Aug 23, 2022 07:02 AM Can-Fite's (CANF) Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Aug 17, 2022 07:26 AM Can-Fite BioPharma (CANF) Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix

Jul 11, 2022 10:36 AM Dawson James Reiterates Buy Rating, $5 Price Target on Can-Fite BioPharma (CANF)

Jul 11, 2022 07:01 AM Can-Fite BioPharma (CANF) to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Jun 29, 2022 08:20 AM Dawson James Reiterates Buy Rating, $5 Price Target on Can-Fite BioPharma (CANF) on Piclidenoson Data

Jun 29, 2022 07:00 AM Can-Fite BioPharma (CANF) Reports Positive Top-Line Results from Piclidenoson Phase III COMFORT Trial

Jun 24, 2022 07:01 AM Can-Fite BioPharma (CANF) Reports CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model

Jun 9, 2022 07:01 AM Can-Fite BioPharma (CANF) Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal

Mar 14, 2022 07:02 AM Can-Fite BioPharma (CANF) Announces Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office

Mar 8, 2022 09:35 AM Dawson James Reiterates Can-Fite (CANF) at Buy with $5 PT Ahead of Psoriasis Data

Mar 8, 2022 07:00 AM Can-Fite BioPharma (CANF) Expects Phase III Psoriasis Study Data in Q2 2022

Dec 29, 2021 07:04 AM Can-Fite BioPharma (CANF) Announces Filing of Patent Applications for the Treatment of Various Advanced Solid Tumors

Dec 20, 2021 12:56 PM Dawson James Reiterates Buy Rating on Can-Fite BioPharma (CANF) on Complete Response in Liver Cancer

Dec 20, 2021 07:04 AM Can-Fite BioPharma (CANF) Announces Liver Cancer Patient Treated with its Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Dec 7, 2021 07:06 AM Can-Fite BioPharma (CANF) Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022

Nov 1, 2021 07:01 AM Can-Fite BioPharma (CANF) Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD

Oct 28, 2021 07:22 AM Can-Fite BioPharma (CANF) NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico

Oct 21, 2021 07:02 AM Can-Fite BioPharma (CANF) Publishes Positive Data from Phase IIa Can-Fite NASH Study

Aug 12, 2021 08:01 AM Can-Fite BioPharma (CANF) Announces $10M Direct Offering

Jul 8, 2021 07:10 AM Can-Fite BioPharma (CANF) Gears Up to Initiate Pivotal Phase III Liver Cancer Study

Jun 28, 2021 07:10 AM Can-Fite BioPharma (CANF) Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets

Jun 24, 2021 10:24 AM Aegis Capital Starts Can-Fite BioPharma (CANF) at Buy

Jun 16, 2021 07:45 AM Can-Fite BioPharma (CANF) Receives Notice of Patent Allowance in China for NASH Treatment

Jun 2, 2021 07:36 AM Can-Fite BioPharma (CANF) Initiate Phase IIb NASH Study in Isreal

Apr 29, 2021 07:46 AM Can-Fite BioPharma (CANF) Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021

Apr 22, 2021 07:21 AM Can-Fite BioPharma (CANF) Expands its Phase II COVID-19 Study to Europe

Apr 5, 2021 07:08 AM Can-Fite BioPharma (CANF) Announces Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies

Mar 30, 2021 08:07 AM Can-Fite BioPharma (CANF) Announces Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million